en
Scientific article
Open access
English

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Published inJournal of hepatology, vol. 66, no. 1, p. 132-141
Publication date2017
Abstract

To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models of NAFLD.

Citation (ISO format)
GARIANI, Karim et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. In: Journal of hepatology, 2017, vol. 66, n° 1, p. 132–141. doi: 10.1016/j.jhep.2016.08.024
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0168-8278
517views
311downloads

Technical informations

Creation10/24/2016 3:46:00 PM
First validation10/24/2016 3:46:00 PM
Update time03/15/2023 12:57:16 AM
Status update03/15/2023 12:57:15 AM
Last indexation01/16/2024 10:18:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack